[1]
Stratigos, A., Sekulic, A., Peris, K., Bechter, O., Kaatz, M., Lewis, K., Basset-Segiun, N., Chang, A.L., Dalle, S., Orland, A.F., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M., Dummer, R., Li, S., Mohan, K., Coates, E., Jankovic, V., Flaschi, N., Okoye, E., Bassukas, I., Loquai, C., De Giorgi, V., Eroglu, Z., Gutzmer, R., Ulrich, J., Puig, S., Seebach, F., Thurston, G., Lowy, I., Bowler, T. and Fury, M. 2021. Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s4. DOI:https://doi.org/10.25251/skin.5.supp.4.